Building the Data Backbone for Direct-to-Patient Drug Sales
How to build the data backbone for direct-to-patient drug sales
Summary
The direct-to-patient (DTP) drug distribution model is gaining importance due to increased access and transparency. Success requires an interoperable data infrastructure that securely and quickly links data from e-prescriptions through benefit verification.
Details
As healthcare delivery decentralizes, Direct-to-Patient (DTP) distribution has emerged as a pivotal model for increasing access and transparency. Scaling DTP requires not only logistics but also a robust technical foundation where health data moves securely and accurately across all participants—patients, prescribers, payers, and manufacturers. The current challenge is that reliance on legacy pharmacy systems or isolated modules leads to inefficient data exchange, increased manual verification processes, higher costs, and eroded patient trust. To succeed, DTP platforms must build a unified, interoperable ecosystem by leveraging FHIR-based integrations and robust APIs, ensuring seamless information flow. This data infrastructure forms a continuous, trustworthy data loop connecting prescribing decisions to outcomes and compliance. Furthermore, combining intelligent automation (e.g., digital prior authorization) with clinical oversight logic ensures efficiency without compromising safety. Transparency is key: patients gain visibility into status and costs, while prescribers can monitor adherence directly from their EHRs. Organizations must establish a unified data layer interoperable with EHRs and payers, implement workflow automation for benefit verification, and maintain robust compliance features (like HIPAA-compliant audit trails) to support the future of DTP.
Technology Note
FHIR（Fast Healthcare Interoperability Resources）は医療データ交換の国際標準。このエントリの関連技術: FHIR
Original content copyright by respective publishers